Effects of alanyl-glutamine on CD4+, CD8+ lymphocyte, IL-8, TNF-α of patients with AECOPD

Objective To observe the changes of CD4+,CD8+ lymphocyte,IL-8 and TNF-o of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) after intravenous feeding of alanylglutamine.Methods We supplemented alanyl-glutamine by phleboclysis for AECOPD patients.The level of IL8,TNF-α were tested by enzyme-linked immunosorbent assay (ELISA),and CD4+ and CD8+ lymphocyte in peripheral blood were detected by flowcytometry in AECOPD patients.SPSS 13.0 software was used to analyze the data.Results Compared to control group,the rate of clinical remission in alanyl-glutamine therapy group was higher (93.33％ vs 73.33％).On the 7th day,the levels of IL-8 (102.11 ± 13.57) ng/ml TNF-α (0.83 ± 0.26) μ g/ L in AG therapy group were lower than those in control group (137.46 ± 12.9) ng/ml and (1.34 ± 0.42) μ g/L,all P ＜ 0.05; but the number of CD3+ lymphocyte in AG therapy group (0.69 × 109)/L was more than that of control group (0.50 × 109)/L,P ＜ 0.05.There was no statistical significant difference in the ratio of CD4+/CD8+ lymphocyte between AG therapy group and control group.Conclusion Glutamine can boost the proliferation of T lymphocyte,at the same time,reduce the expression of IL-8 and TNF-o,thus making it have treatment effect on AECOPD. Key words: Alanyl-glutamine;  Acute exacerbation of chronic obstructive pulmonary disease;  CD4+,CD8+ lymphocyte;  Mediators of inflammation